Abscopal-Effekt in der Therapie des malignen Melanoms

Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells

(2014) S. Matsumura et al.   JOURNAL OF IMMUNOLOGY

Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma

(2013) B Sherrill et al.   BRITISH JOURNAL OF CANCER

Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients

(2013) Trine Zeeberg Iversen et al.   OncoImmunology

Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment

(2013) Sandra Demaria et al.   OncoImmunology

Melanoma brain metastasis: overview of current management and emerging targeted therapies

(2012) Ekokobe Fonkem et al.   Expert Review of Neurotherapeutics

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

(2012) Anna Maria Di Giacomo et al.   LANCET ONCOLOGY

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

(2012) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and clinical activity of ipilimumab in melanoma patients with brain metastases

(2011) Jeffrey S. Weber et al.   MELANOMA RESEARCH

Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody

(2009) M. Z. Dewan et al.   CLINICAL CANCER RESEARCH

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS

(2008) F Stephen Hodi et al.   Nature clinical practice. Oncology